Irmina Diala
Overview
Explore the profile of Irmina Diala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Liu H, Pearson T, Iwase T, Fuson J, Lalani A, et al.
Biomedicines
. 2021 Jul;
9(7).
PMID: 34203351
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to...
2.
Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea M, et al.
NPJ Breast Cancer
. 2021 May;
7(1):63.
PMID: 34045483
Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib...
3.
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Conlon N, Kooijman J, van Gerwen S, Mulder W, Zaman G, Diala I, et al.
Br J Cancer
. 2021 Jan;
124(7):1249-1259.
PMID: 33473169
Background: Human epidermal growth factor 2 (HER2/ERBB2) is frequently amplified/mutated in cancer. The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive breast cancer....
4.
Zhao M, Scott S, Evans K, Yuca E, Saridogan T, Zheng X, et al.
Clin Cancer Res
. 2021 Jan;
27(6):1681-1694.
PMID: 33414137
Purpose: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA approved for HER2-overexpressing/amplified (HER2) breast cancer. In this preclinical study, we explored the efficacy of neratinib in combination...
5.
Diala I, Shiohama Y, Fujita T, Kotake Y, Demonacos C, Krstic-Demonacos M, et al.
Nucleosides Nucleotides Nucleic Acids
. 2020 Apr;
39(1-3):407-425.
PMID: 32310030
Telomerase activity has been regarded as a critical step in cellular immortalization and carcinogenesis and because of this, regulation of telomerase represents an attractive target for anti-tumor specific therapeutics. Recently,...
6.
Li B, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, et al.
Cancer Discov
. 2020 Mar;
10(5):674-687.
PMID: 32213539
Amplification of and oncogenic mutations in , the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather...
7.
Ivanova E, Kuraguchi M, Xu M, Portell A, Taus L, Diala I, et al.
Clin Cancer Res
. 2020 Feb;
26(10):2393-2403.
PMID: 32034078
Purpose: Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in mutant...
8.
Lysyy T, Lalani A, Olek E, Diala I, Geibel J
Pharmacol Res Perspect
. 2019 Sep;
7(5):e00521.
PMID: 31523434
Diarrhea is one of the most commonly reported adverse effect of hemotherapy and targeted cancer therapies, such as tyrosine kinase inhibitors (TKI), which often significantly impact patient quality of life,...
9.
Nagpal A, Redvers R, Ling X, Ayton S, Fuentes M, Tavancheh E, et al.
Breast Cancer Res
. 2019 Aug;
21(1):94.
PMID: 31409375
Background: Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of patients...
10.
Booth L, Roberts J, Rais R, Cutler Jr R, Diala I, Lalani A, et al.
J Cell Physiol
. 2018 Sep;
234(4):4874-4887.
PMID: 30203445
Regorafenib is approved for the treatment of colorectal cancer and hepatocellular carcinoma. In the trial NCT02466802, we have discovered that regorafenib can be safely combined with the phosphodiesterase 5 inhibitor...